Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H9NO2 |
Molecular Weight | 151.1626 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(O)C=C1
InChI
InChIKey=RZVAJINKPMORJF-UHFFFAOYSA-N
InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)
Molecular Formula | C8H9NO2 |
Molecular Weight | 151.1626 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. Acetaminophen (USAN) or Paracetamol (INN) is a widely used analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. At therapeutic doses, acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, kidney function, or the fetal ductus arteriosus (as NSAIDs can). Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. Acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells, which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. The antipyretic properties of acetaminophen are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in peripheral vasodilation, sweating and hence heat dissipation.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15662292 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5798721E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date7.5790077E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43 μg × h/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/ Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 2300 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 5300 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
major | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1500 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1900 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 2300 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 3700 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 4000 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 5500 uM] | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Massive hemolysis caused by acetaminophen. Positive determination by direct Coombs test. | 1976 Dec 13 |
|
Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. | 1979 Feb 10 |
|
An experimental study on the disorders of hepatic hemodynamics and changes of plasma histamine in dogs with fulminant hepatic failure. | 1998 |
|
Isolated acute renal failure due to paracetamol intoxication in an alcoholic patient. | 1999 |
|
Paracetamol-induced fulminant hepatic failure in a child after 5 days of therapeutic doses. | 1999 |
|
Early metabolic acidosis and coma after acetaminophen ingestion. | 1999 Apr |
|
Assay to detect inhibitory substances in serum of patients with acute liver failure. | 1999 Feb |
|
Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 rats. | 1999 Jan 8 |
|
Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. | 1999 Jul |
|
Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. | 1999 Jun |
|
Characteristics and risk factors of acetaminophen-induced hepatitis in Taiwan. | 1999 Jun |
|
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
Accidental paracetamol overdosing and fulminant hepatic failure in children. | 1999 Nov 1 |
|
Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. | 1999 Sep |
|
[Does TNF-alpha contribute to liver disease physiopathology?]. | 2000 |
|
The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. | 2000 Apr |
|
The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. | 2000 Apr |
|
Time to onset of analgesia and analgesic efficacy of effervescent acetaminophen 1000 mg compared to tablet acetaminophen 1000 mg in postoperative dental pain: a single-dose, double-blind, randomized, placebo-controlled study. | 2000 Apr |
|
Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children. | 2000 Apr |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
Acetaminophen produces cataract in DBA2 mice by Ah receptor-independent induction of CYP1A2. | 2000 Aug |
|
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. | 2000 Aug |
|
Hepatocellular response to chemical stress in CD-1 mice: induction of early genes and gamma-glutamylcysteine synthetase. | 2000 Aug |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
Energy expenditure in acetaminophen-induced fulminant hepatic failure. | 2000 Mar |
|
N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). | 2000 May-Jun |
|
Mechanism of action of acetaminophen: is there a cyclooxygenase 3? | 2000 Oct |
|
Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. | 2000 Oct |
|
Effects of acetaminophen administration to patients in intensive care. | 2000 Sep |
|
A prospective study of gastric mucosal ischaemia in paracetamol-induced acute liver failure. | 2000 Sep |
|
Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat. | 2000 Sep |
|
p-Aminophenol-induced liver toxicity: tentative evidence of a role for acetaminophen. | 2001 |
|
Urine drug screens in overdose patients do not contribute to immediate clinical management. | 2001 Feb |
|
Stroke severity determines body temperature in acute stroke. | 2001 Feb |
|
Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. | 2001 Feb 10 |
|
Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients. | 2001 Feb 13 |
|
[About paracetamol again]. | 2001 Feb 18 |
|
ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease. | 2001 Feb 3 |
|
Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. | 2001 Jan |
|
A comparison of the effect of nitroparacetamol and paracetamol on liver injury. | 2001 Jan |
|
Treatment with paracetamol in infants. | 2001 Jan |
|
Gastric emptying in diabetic gastroparetic dogs: ffects of SK-951,a novel prokinetic agent. | 2001 Jan |
|
Safety of childhood acetaminophen overdose. | 2001 Jan |
|
Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. | 2001 Jan |
|
Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow? | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
[Dexketoprofen-trometamol and tramadol in acute lumbago]. | 2001 Jan 11 |
|
Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. | 2001 Jan 26 |
|
Experimental and theoretical microdialysis studies of in situ metabolism. | 2001 Mar |
|
A comparison of ropivacaine and bupivacaine for cervical plexus block. | 2001 Mar |
Patents
Sample Use Guides
2 caplets every 8 hours with water; don't take more than 6 caplets in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10751557
A time- and concentration-dependent decrease in intracellular GSH occurred in freshly isolated type II pneumocytes and alveolar macrophages exposed to subtoxic (= 1 mM) APAP concentrations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 19:19:58 UTC 2022
by
admin
on
Sun Dec 18 19:19:58 UTC 2022
|
Record UNII |
362O9ITL9D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AJ17
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
CFR |
21 CFR 341.40
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-VATC |
QN02BE71
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
||
|
NCI_THESAURUS |
C2356
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
||
|
WHO-VATC |
QN02BE01
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
||
|
WHO-ATC |
N02AJ06
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
CFR |
21 CFR 862.3030
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ATC |
N02BE71
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
EPA PESTICIDE CODE |
606318
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-VATC |
QN02BE51
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
||
|
LOINC |
75071-1
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ATC |
N02BE51
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ATC |
N02BE01
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ATC |
N02AJ13
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
||
|
LIVERTOX |
NBK548162
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
||
|
WHO-ATC |
N02AJ01
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1003009
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
PRIMARY | |||
|
SUB09611MIG
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
DTXSID2020006
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
362O9ITL9D
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
1983
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
DB00316
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
PARACETAMOL
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
PRIMARY | |||
|
8055-08-1
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
SUPERSEDED | |||
|
Acetaminophen
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
M1317
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | Merck Index | ||
|
ACETAMINOPHEN
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Sparingly soluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R; practically insoluble in ether R. Category: Analgesic; antipyretic. Storage: Paracetamol should be kept in a tightly closed container, protected from light. Definition: Paracetamol contains not less than 98.5% and not more than 101.0% of C8H9NO2, calculated with reference to thedried substance. | ||
|
626
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
109028
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
203-157-5
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
362O9ITL9D
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
CHEMBL112
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
52
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
161
Created by
admin on Sun Dec 18 19:20:06 UTC 2022 , Edited by admin on Sun Dec 18 19:20:06 UTC 2022
|
PRIMARY | RxNorm | ||
|
3001
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
46195
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
3991
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
D000082
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
103-90-2
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
5239
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY | |||
|
C198
Created by
admin on Sun Dec 18 19:20:05 UTC 2022 , Edited by admin on Sun Dec 18 19:20:05 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Enzyme responsible for the bulk of NAPQI formation
MAJOR
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE ACTIVE |
Percent of dose excreted in urine as metabolite.
AMOUNT ADMINISTERED
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
PARENT -> METABOLITE ACTIVE |
Percent of dose excreted in urine as metabolite 60-80
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
May be substrate for formation of AM-404
MINOR
|
||
|
METABOLITE TOXIC -> PARENT |
Metabolite produced hepatic necrosis in man.
AMOUNT EXCRETED
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
IV, LESS THAN 50 Kg |
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
RENAL CLEARANCE | PHARMACOKINETIC |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||